Alcista
$22.20
Precio del escenario
$16.370
-0.285 (-1.74%)Al cierre
Hercules Capital, Inc. is a specialty finance company. The Company is focused on providing senior secured loans to venture capital-backed and institutional-backed companies in a variety of technology and life sciences industries. It is structured as an internally managed, non-diversified, closed-end investment company. Its business objectives are to increase its net income, net investment income, and net asset value, through its investments in primarily structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It invests in a range of companies active in the technology industry sub-sectors characterized by products or services that require advanced technologies, including computer software and hardware, networking systems, semiconductors, telecommunications equipment and media, semiconductor capital equipment, information technology infrastructure, and others.
Hercules Capital is currently priced at $16.51, with a forward P/E ratio of 8.61, indicating it may be undervalued compared to its earnings potential. However, the RSI is at 34.17, suggesting the stock is oversold and may continue to face downward pressure in the short term. The main risk is the recent decline in net income, which fell to $41.66 million in Q1 2026, down from $61.83 million in Q4 2025, indicating potential volatility in earnings.
UBS
—
2026-09-01
UBS
2026-09-01
Precio objetivo
—
Ladenburg
$20
2026-07-31
Ladenburg
2026-07-31
Precio objetivo
$20
UBS
$15
2026-05-18
UBS
2026-05-18
Precio objetivo
$15
Ladenburg
$21
2026-05-06
Ladenburg
2026-05-06
Precio objetivo
$21
Piper Sandler
$17
2026-05-06
Piper Sandler
2026-05-06
Precio objetivo
$17
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

Hercules Capital Secures Fitch BBB Rating Affirmation

Hercules Capital Closes $400 Million Note Offering

Rocket Pharmaceuticals Secures $150 Million Credit Facility

Hercules Capital Announces $400 Million Note Offering

Hercules Capital Raises $2.3 Billion in New Equity Commitments
Hercules Capital, Inc. is a specialty finance company. The Company is focused on providing senior secured loans to venture capital-backed and institutional-backed companies in a variety of technology and life sciences industries. It is structured as an internally managed, non-diversified, closed-end investment company. Its business objectives are to increase its net income, net investment income, and net asset value, through its investments in primarily structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It invests in a range of companies active in the technology industry sub-sectors characterized by products or services that require advanced technologies, including computer software and hardware, networking systems, semiconductors, telecommunications equipment and media, semiconductor capital equipment, information technology infrastructure, and others. It operates in the Financials sector.
Hercules Capital is currently priced at $16.51, with a forward P/E ratio of 8.61, indicating it may be undervalued compared to its earnings potential. However, the RSI is at 34.17, suggesting the stock is oversold and may continue to face downward pressure in the short term. The main risk is the recent decline in net income, which fell to $41.66 million in Q1 2026, down from $61.83 million in Q4 2025, indicating potential volatility in earnings.
11 analysts cover HTGC: 7 rate it Buy, 4 Hold and 0 Sell. The average price target is 20.04.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.